CARMAT Announces the First Implantation of Aeson Within the Framework of The EFICAS Clinical Study in France

Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering

Related Keywords

United States ,Bois Darcy ,Bourgogne ,France ,Rennes ,Bretagne ,Paris ,France General ,Villacoublay ,French ,Dusan Oresansky ,Enregistrement Universel ,Caroline Carmagnol ,Linkedin ,Strasbourg University Hospital ,Lyon University Hospital Hospices Civils De ,French National Innovation Fund ,University Hospital ,European Union ,Rennes University Hospital ,Food Drug Administration ,Lille Regional University Hospital ,Regulatory News ,Lille Regional University ,Georges Pompidou European Hospital ,Lyon University Hospital ,Hospices Civils De Lyon ,Chief Executive Officer ,Professor Andr ,French Medtech ,Early Feasibility Study ,Euronext Growth ,Universal Registration Document ,Des March ,Executive Officer ,Financial Officer ,Carmat ,Nnounces ,First ,Implantation ,Beeson ,Ithin ,Framework ,Ficas ,Linical ,Study ,